The Design of a Series of Highly A2 Selective Adenosine Agonists

  • A. J. Hutchison
  • H. Oei
  • M. Jarvis
  • M. Williams
  • R. L. Webb
Conference paper


The purine nucleoside, adenosine has been extensively studied as a modulator of cardiovascular function since it was shown to have potent hypotensive and bradycardic activity some 60 years ago (Drury et al., 1929). The hypotensive actions of adenosine occur via several mechanisms among which are direct regulation of blood flow via vasodilation of the peripheral vasculature, including the coronary arteries (Berne et al., 1983). Adenosine also produces sinus bradycardia and prolongation of impluse conduction in the atrioventricular node (Bellardinelli et al., 1983). In addition, adenosine has the ability to inhibit neurotransmitter release (Fredholm et al., 1988) and possesses potent central nervous system depressant and anticonvulsant activity (Dunwiddie, 1985).


Potential Intracellular Action Adenosine Receptor Subtype Fold Selectivity Receptor Binding Profile Inhibit Neurotransmitter Release 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bellardinelli, L., West, A., Crampton, R., and Berne, R.M., 1983, In Regulatory Function of Adenosine. (Eds. Berne, R.M.; Rail, T.W.; Rubio, R.) Nihoff, Boston, p.378.Google Scholar
  2. Berne, R.M., Winn, H.R., Knabb, R.M., Ely, S.W., and Rubio, R., 1983, In Regulatory Function of Adenosine. (Eds. Berne, R.M.; Rall, T.W.; Rubio, R.) Nihoff, Boston, p.293.Google Scholar
  3. Bridges, A.J., Bruns, R.F., Ortwine, D.F., Priebe, S.R., Szotek, D.L., and Trivedi, B.K., 1988, J. Med. Chem. 31:1282.PubMedCrossRefGoogle Scholar
  4. Bruns, R.F., Lu, G.H., and Pugsley, T.A., 1986, Mol. Pharmacol. 29:331.PubMedGoogle Scholar
  5. Daly, J.W., 1982, J. Med. Chem. 25:197.PubMedCrossRefGoogle Scholar
  6. Drury, A.N., and Szent-Gyorgyi, A., 1929, J. Physiol. (Lond.)) 68:214.Google Scholar
  7. Dunwiddie, T.V., 1985, Inter. Rev. Neurobiol. 25:63.CrossRefGoogle Scholar
  8. Fredholm, B., and Dunwiddie, T.V., 1988, Trends Pharmacol. Sci. 9:130.PubMedCrossRefGoogle Scholar
  9. Hutchison, A.J., Oei, H.H., Ghai, G.R., and Williams M., 1989, FASEB J. 3:A281.Google Scholar
  10. Krulan, C., Wang, Z.C., Jeng, A.Y., Chen, J., and Balwierczak, J.L., 1989, FASEB J. 3:A1048.Google Scholar
  11. Neely, J.R., Liebermeister, H., Battersby, E.J., and Morgan, H.E., 1967, Am. J. Physiol. 212:804.PubMedGoogle Scholar
  12. Sylven, C., Beermann, B., Jonzon, B., and Brandt, R., 1986, Br. Med. J. 293:227.CrossRefGoogle Scholar
  13. Stein, H.H., Prasad, R.N., Tietje, K.R., and Fung, A.K.L., 1979, U.S. Patent 4,167,565.Google Scholar
  14. Williams, M., Braunwalder, A., and Erickson, T.E., 1986, Naunyn-Schmiedberg’s Arch. Pharmacol. 332:179.CrossRefGoogle Scholar
  15. Williams, M., Schulz, R., Hutchison, A.J., Do, E., Sills, M.A., and Jarvis, M.F., 1989, FASEB J. 3:A1047.Google Scholar

Copyright information

© Springer-Verlag New York Inc. 1990

Authors and Affiliations

  • A. J. Hutchison
  • H. Oei
  • M. Jarvis
  • M. Williams
  • R. L. Webb

There are no affiliations available

Personalised recommendations